167 related articles for article (PubMed ID: 38659291)
1. Are we ready for genetic testing in metabolic dysfunction-associated steatotic liver disease?
Tulone A; Pennisi G; Ciccioli C; Infantino G; La Mantia C; Cannella R; Mercurio F; Petta S
United European Gastroenterol J; 2024 Jun; 12(5):638-648. PubMed ID: 38659291
[TBL] [Abstract][Full Text] [Related]
2. Familial coaggregation of MASLD with hepatocellular carcinoma and adverse liver outcomes: Nationwide multigenerational cohort study.
Ebrahimi F; Hagström H; Sun J; Bergman D; Shang Y; Yang W; Roelstraete B; Ludvigsson JF
J Hepatol; 2023 Dec; 79(6):1374-1384. PubMed ID: 37647992
[TBL] [Abstract][Full Text] [Related]
3. Histidine-rich glycoprotein in metabolic dysfunction-associated steatohepatitis-related disease progression and liver carcinogenesis.
Foglia B; Sutti S; Cannito S; Rosso C; Maggiora M; Casalino A; Bocca C; Novo E; Protopapa F; Ramavath NN; Provera A; Gambella A; Bugianesi E; Tacke F; Albano E; Parola M
Front Immunol; 2024; 15():1342404. PubMed ID: 38469298
[TBL] [Abstract][Full Text] [Related]
4. Metabolic dysfunction-associated steatotic liver disease: Navigating terminological evolution, diagnostic frontiers and therapeutic horizon-an editorial exploration.
Boldys A; Buldak L
World J Gastroenterol; 2024 May; 30(18):2387-2390. PubMed ID: 38764762
[TBL] [Abstract][Full Text] [Related]
5. Monitoring disease progression in metabolic dysfunction-associated steatotic liver disease.
Noureddin N; Copur-Dahi N; Loomba R
Aliment Pharmacol Ther; 2024 Jun; 59 Suppl 1(Suppl 1):S41-S51. PubMed ID: 38813822
[TBL] [Abstract][Full Text] [Related]
6. Natural history of metabolic dysfunction-associated steatotic liver disease.
Lekakis V; Papatheodoridis GV
Eur J Intern Med; 2024 Apr; 122():3-10. PubMed ID: 37940495
[TBL] [Abstract][Full Text] [Related]
7. Roles of immune dysregulation in MASLD.
Dong T; Li J; Liu Y; Zhou S; Wei X; Hua H; Tang K; Zhang X; Wang Y; Wu Z; Gao C; Zhang H
Biomed Pharmacother; 2024 Jan; 170():116069. PubMed ID: 38147736
[TBL] [Abstract][Full Text] [Related]
8. Screening, Diagnosis, and Staging of Non-Alcoholic Fatty Liver Disease (NAFLD): Application of Society Guidelines to Clinical Practice.
Ilagan-Ying YC; Banini BA; Do A; Lam R; Lim JK
Curr Gastroenterol Rep; 2023 Oct; 25(10):213-224. PubMed ID: 37768417
[TBL] [Abstract][Full Text] [Related]
9. The double roles of T cell-mediated immune response in the progression of MASLD.
Li Z; Wang S; Xu Q; Su X; Wang Y; Wang L; Zhang Y
Biomed Pharmacother; 2024 Apr; 173():116333. PubMed ID: 38479177
[TBL] [Abstract][Full Text] [Related]
10. EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD): Executive Summary.
; ; ;
Diabetologia; 2024 Jun; ():. PubMed ID: 38869512
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic management of metabolic dysfunction associated steatotic liver disease.
Zeng J; Fan JG; Francque SM
United European Gastroenterol J; 2024 Mar; 12(2):177-186. PubMed ID: 38193865
[TBL] [Abstract][Full Text] [Related]
12. Saturated Fat-Mediated Upregulation of IL-32 and CCL20 in Hepatocytes Contributes to Higher Expression of These Fibrosis-Driving Molecules in MASLD.
Schilcher K; Dayoub R; Kubitza M; Riepl J; Klein K; Buechler C; Melter M; Weiss TS
Int J Mol Sci; 2023 Aug; 24(17):. PubMed ID: 37686029
[TBL] [Abstract][Full Text] [Related]
13. Sex-based differences in natural killer T cell-mediated protection against diet-induced steatohepatitis in Balb/c mice.
Cuño-Gómiz C; de Gregorio E; Tutusaus A; Rider P; Andrés-Sánchez N; Colell A; Morales A; Marí M
Biol Sex Differ; 2023 Nov; 14(1):85. PubMed ID: 37964320
[TBL] [Abstract][Full Text] [Related]
14. Guideline-based management of metabolic dysfunction-associated steatotic liver disease in the primary care setting.
Allen AM; Charlton M; Cusi K; Harrison SA; Kowdley KV; Noureddin M; Shubrook JH
Postgrad Med; 2024 Apr; 136(3):229-245. PubMed ID: 38465573
[TBL] [Abstract][Full Text] [Related]
15. Pathology and Pathogenesis of Metabolic Dysfunction-Associated Steatotic Liver Disease-Associated Hepatic Tumors.
Takahashi Y; Dungubat E; Kusano H; Fukusato T
Biomedicines; 2023 Oct; 11(10):. PubMed ID: 37893134
[TBL] [Abstract][Full Text] [Related]
16. Regulatory T cell: a double-edged sword from metabolic-dysfunction-associated steatohepatitis to hepatocellular carcinoma.
Wang H; Tsung A; Mishra L; Huang H
EBioMedicine; 2024 Mar; 101():105031. PubMed ID: 38401419
[TBL] [Abstract][Full Text] [Related]
17. Liver biopsy-based validation, confirmation and comparison of the diagnostic performance of established and novel non-invasive steatotic liver disease indexes: Results from a large multi-center study.
Kouvari M; Valenzuela-Vallejo L; Guatibonza-Garcia V; Polyzos SA; Deng Y; Kokkorakis M; Agraz M; Mylonakis SC; Katsarou A; Verrastro O; Markakis G; Eslam M; Papatheodoridis G; George J; Mingrone G; Mantzoros CS
Metabolism; 2023 Oct; 147():155666. PubMed ID: 37527759
[TBL] [Abstract][Full Text] [Related]
18. Review article: the emerging role of genetics in precision medicine for patients with non-alcoholic steatohepatitis.
Carlsson B; Lindén D; Brolén G; Liljeblad M; Bjursell M; Romeo S; Loomba R
Aliment Pharmacol Ther; 2020 Jun; 51(12):1305-1320. PubMed ID: 32383295
[TBL] [Abstract][Full Text] [Related]
19. Comprehensive meta-analysis reveals distinct gene expression signatures of MASLD progression.
Piras IS; DiStefano JK
Life Sci Alliance; 2024 Jun; 7(6):. PubMed ID: 38565287
[TBL] [Abstract][Full Text] [Related]
20. Non-invasive Scores and Serum Biomarkers for Fatty Liver in the Era of Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD): A Comprehensive Review From NAFLD to MAFLD and MASLD.
Abdelhameed F; Kite C; Lagojda L; Dallaway A; Chatha KK; Chaggar SS; Dalamaga M; Kassi E; Kyrou I; Randeva HS
Curr Obes Rep; 2024 May; ():. PubMed ID: 38809396
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
